Abstract
THIS REPORT:
- Presents a comprehensive analysis of the emerging global DNA vaccine
industry
- Forecasts sales in the global market for DNA vaccines through 2014
- Highlights products and technologies that are commercially important in
the 2009 to 2014 time period
- Quantifies the DNA vaccines market potential by disease, end use market
and technology
- Identifies emerging growth opportunities in DNA vaccine delivery
technologies, adjuvants and synthetic genes
- Includes company profiles along with patents by technology and patents by
company.
SCOPE OF REPORT
The study scope includes DNA vaccine products that are commercial or likely to
be commercialized within the next 5 years. Both human and animal health
markets are studied. DNA vaccine delivery technologies are also included. DNA
vaccine candidates in clinical trials are examined by indication, and future
market growth from 2009 through 2014 is estimated.
The role that DNA vaccines play in the overall vaccines industry is examined,
as well as how the vaccine industry structure and dynamics are changing.
We examine DNA synthesis, biotechnology, and pharmaceuticals firms; strategic
industry alliances; and the role of gene delivery and synthesis technologies.
The major markets for DNA vaccines, including infectious diseases, cancers,
animal health, allergies, and biodefense, are analyzed and the main companies
in these fields are highlighted.
METHODOLOGY
Both primary and secondary research methodologies were used to prepare this
report. BCC Research surveyed key users and producers in each of the end-user
market segments and technology fields that will be commercially important
during the next 5 years. Interviews with industry thought leaders were
conducted, and an extensive review of secondary sources was done, as well as
secondary market research was performed.
A vaccine value-chain method is used to study competitor, technology, and
market positioning.
Based on our analysis, we project the future applications of DNA vaccines by
market segment and technology type, and forecast sales revenues for 2009
through 2014.
INFORMATION SOURCES
BCC surveyed biotechnology, pharmaceutical, and gene synthesis companies to
obtain data for this study. Included were life-science research tools, drug,
biotechnology, DNA synthesis firms, as well as leading life-science research
institutions. We also spoke with industry thought leaders. In addition, we
compiled data from secondary sources, including industry, trade, and
government.
ANALYST CREDENTIALS
The author, John Bergin, has written previous BCC biotechnology reports
entitled Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and
Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA
Interference in the Post-Genomics Era: Markets and Technologies; DNA
Sequencing: Emerging Technologies and Markets; Biologic Imaging Reagents:
Future Technologies and Markets and Synthetic Biology. Mr. Bergin has held
business development, sales and marketing positions with a Fortune 500
advanced materials company, as well as executive management positions with an
emerging nanotechnology company. Mr. Bergin holds the following degrees: B.S.
Chemistry, M.S. Biotechnology, and Masters of Business Administration.
| 
View Cart
